Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2007
11/22/2007WO2007131424A1 Method for preparing low molecular weight proteoglycan and collagen compositions, its products and uses
11/22/2007WO2007131366A1 Iap bir domain binding compounds
11/22/2007WO2007131365A1 Treatment of neoplastic disorders using a farnesyl dibenzodiazepinone administered by continuous intravenous infusion
11/22/2007WO2007131364A1 Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
11/22/2007WO2007131357A1 Pharmaceutical composition having reduced abuse potential
11/22/2007WO2007131350A1 Inhibitors of human immunodeficiency virus replication
11/22/2007WO2007131329A1 Treatment of ubiquitin-proteasome system dysfunction related disorders
11/22/2007WO2007131310A1 Anti-inflammatory and analgesic pharmaceutical composition containing safrole n-acylhydrazone derivatives, use, and method of preparation
11/22/2007WO2007131300A1 Polypeptides and polynucleotides encoding the same
11/22/2007WO2007131286A1 Nanostructures suitable for delivery of agents
11/22/2007WO2007131274A1 Short interference ribonucleic acids for treating allegic diseases
11/22/2007WO2007131253A2 Use of combination preparations comprising antifungal agents
11/22/2007WO2007120595A3 Amines for the treatment of hcv
11/22/2007WO2007117482A3 Renin inhibitors
11/22/2007WO2007115020A3 Therapeutic prostaglandin compounds for the treatment of glaucoma
11/22/2007WO2007112399A3 Tetrahydro-pyrazolo[3,4-c]pyridine cannabinoid modulators
11/22/2007WO2007111626A3 Arginase ii: a target for the prevention and treatment of atherosclerosis
11/22/2007WO2007110627A3 3,7-diamino-10h-phenothiazine salts and their use
11/22/2007WO2007109330A3 S1p receptor modulating compounds
11/22/2007WO2007109141A3 Pharmaceutical compositions for intranasal administration comprising a melatonin receptor agonist, uses thereof
11/22/2007WO2007108004A8 S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
11/22/2007WO2007108002A3 Use of digitalis-like compounds in the treatment of affective disorders
11/22/2007WO2007107663A3 Use of (3s)-n-hydroxy-4-({4-[(4-hydroxy-2-butynyl)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide or (s)-n-hydroxy-4-(4-but-2-ynyloxy-benzenesulfonyl) -2,2-dimethyl-thiomorpholine -3-carboxamide for treating inflammatory skin pathologies
11/22/2007WO2007106576A3 Methods and materials for immunization against cancer
11/22/2007WO2007106436A3 Photoactive compounds and compositions and uses thereof
11/22/2007WO2007106317A3 Pharmaceutical combinations of hcv-protease and -ires inhibitors
11/22/2007WO2007105021A3 Duloxetine salts
11/22/2007WO2007104772A9 Novel enantiomerically pure beta-agonists, method for their production and their use as medicaments
11/22/2007WO2007103877A3 Pharmaceutical formulations of a monohydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
11/22/2007WO2007103432A3 Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders
11/22/2007WO2007103273A3 Thioredoxin and thioredoxin reductase inhibitors
11/22/2007WO2007103110A3 Reduction of the titratable acidity and the prevention of tooth and other bone degeneration
11/22/2007WO2007100695A9 Metabolic regulators and uses thereof
11/22/2007WO2007099553A3 1,3-dioxane carboxylic acids
11/22/2007WO2007099432A3 Pharmaceutical composition containing butea isoflavones for the prevention /treatment of bone disorders and a process for the preparation thereof
11/22/2007WO2007098868A8 Use of moxifloxacin in combination with cefixime for treatment of infectious diseases caused by gram-positive and gram-negative pathogens
11/22/2007WO2007098247A3 Substituted taraxastanes useful for treating viral infections
11/22/2007WO2007097931A3 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
11/22/2007WO2007095611A3 Use of benzo-fused heteroaryl sulfamide derivatives for the treatment of migraine
11/22/2007WO2007095495A3 Benzodiazepine gcnf modulators for stem cell modulation
11/22/2007WO2007093746A3 Use of muraglitazar for preparing a pharmaceutical composition for treating skin disorders
11/22/2007WO2007093608A8 Drug combinations for the treatment of respiratory tract diseases
11/22/2007WO2007093183A3 Use of a compound that enhances gabaa-ergic neurotransmission for the treatment of inflammatory diseases
11/22/2007WO2007092563A3 Gene therapy for niemann-pick disease type a
11/22/2007WO2007087572A3 Aza-peptide epoxides
11/22/2007WO2007087506A3 Compounds for the treatment of metabolic disorders
11/22/2007WO2007087442A3 Substituted biaryl compounds for inflammation and immune-related uses
11/22/2007WO2007087246A3 Jak2 tyrosine kinase inhibition
11/22/2007WO2007087245A3 Ret tyrosine kinase inhibition
11/22/2007WO2007086995A3 Methylene blue therapy of avian influenza
11/22/2007WO2007086978A3 Azithromycin for treatment of granulomatous rosacea
11/22/2007WO2007084670A3 Specific therapy using integrin ligands for treating cancer
11/22/2007WO2007084614A3 Hair growth formula
11/22/2007WO2007084468A3 Photodynamic cosmetic procedure and healing method
11/22/2007WO2007083316A3 Microspheres comprising nanocapsules containing a lipophilic drug
11/22/2007WO2007081909A3 Forms of dolasetron mesylate and processes for their preparation
11/22/2007WO2007081897A3 Fused triazole tachykinin receptor antagonists
11/22/2007WO2007081091A8 Rhodandse derivarives, a process for the preparation thereof and pharmaceutical composition containing the same
11/22/2007WO2007078990A3 Modified lysine-mimetic compounds
11/22/2007WO2007077961A3 Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands
11/22/2007WO2007076322A3 Compositions and methods for attenuating mitochondria-mediated cell injury
11/22/2007WO2007073489A3 Molecules for gene delivery and gene therapy, and methods of use thereof
11/22/2007WO2007067995A3 Inhibitors of histone deacetylase for the treatment of disease
11/22/2007WO2007065023A3 Processes for obtaining lignan extracts and compositions containing the lignan extracts
11/22/2007WO2007062370A3 Calcilytic compounds
11/22/2007WO2007062314A3 Heterocyclic cetp inhibitors
11/22/2007WO2007061853A3 Process for synthesizing 2-phenyl-1h-phenantrho[9,10-d]imidazole derivative
11/22/2007WO2007059500A3 Novel process and formulations
11/22/2007WO2007059445A3 Synergistic combinations of norketamine and opioid analgesics
11/22/2007WO2007059372A3 Use of chloroquine to treat metabolic syndrome
11/22/2007WO2007057873A3 Novel compositions to improve gut health and animal performance and methods of making the same
11/22/2007WO2007057221A3 Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases
11/22/2007WO2007056771A3 Compounds for the treatment of metabolic disorders
11/22/2007WO2007056525A3 High affinity siglec ligands
11/22/2007WO2007056387A3 Combinations of metformin and meglitinide
11/22/2007WO2007056376A3 Compositions for regulating metabolic disorders and methods of use thereof
11/22/2007WO2007053650A3 Diazonamide a analog
11/22/2007WO2007053558A3 Vancomycin formulations having reduced amount of histamine
11/22/2007WO2007051119A8 Methods and compositions of parp inhibitors as potentiators in cancer therapy
11/22/2007WO2007050802A3 Novel opioid antagonists
11/22/2007WO2007050795A3 Transglutaminase inhibitors and methods of use thereof
11/22/2007WO2007047010A3 Anti-emetic uses of cannabinoid analogs
11/22/2007WO2007046123A3 Composition containing vitamins k and d as well as taurine for the preventio and treatment of osteoporosis
11/22/2007WO2007044885A3 Piperidine derivatives and methods of use
11/22/2007WO2007044641A3 Glutathione peroxidase mimetics and uses thereof
11/22/2007WO2007041587A3 Biomedical bond enhancer
11/22/2007WO2007038669A3 Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
11/22/2007WO2007035963A3 Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
11/22/2007WO2007035954A3 Vaginal tablets comprising misoprostol and methods of making and using the same
11/22/2007WO2007035478A3 Niacin receptor agonists, compositions containing such compounds and methods of treatment
11/22/2007WO2007028000A3 Des-c,d analogs of 1alpha,25-dihydroxy-19-norvitamin d3
11/22/2007WO2007027225A3 Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
11/22/2007WO2007025247A3 Transglutaminase inhibitors and methods of use thereof
11/22/2007WO2007024599A3 Comination of a hypnotic agent and r(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenl)ethyl]-4-piperidinemethanol and therapeutic application thereof
11/22/2007WO2007021968A3 Sustained release antihistamine and decongestant composition
11/22/2007WO2007016677A3 Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
11/22/2007WO2007013987A3 Supplement composition and method of use in enhancement of methylation process
11/22/2007WO2007010557A3 Process for the preparation of highly pure ropinirole
11/22/2007WO2007001323A3 Methods and compositions for inhibiting, destroying, and/or inactivating viruses
11/22/2007WO2006135839A3 Piperazine-piperidine antagonists and agonists of the 5-ht1a receptor
1 ... 3489 3490 3491 3492 3493 3494 3495 3496 3497 3498 3499 3500 3501 3502 3503 3504 3505 3506 3507 3508 3509 ... 7860